GSK reports strong Phase 3 results for Ionis-licensed chronic hepatitis B therapy
GSK disclosed data from two late‑stage trials of a chronic hepatitis B treatment it licensed from Ionis Pharmaceuticals. The studies evaluated the drug’s efficacy and safety in patients with chronic infection.
The results showed a significant improvement over existing standard of care, with higher rates of viral suppression and functional cure markers. Safety profile was consistent with expectations and no new safety signals emerged.
Regulatory reviews are now ongoing in four regions, including the United States, as GSK prepares for potential market launch pending approval.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionis”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that